In follow-up to my Written Question P-001947/2016, the inclusion of the provision of the target for a 30% decrease in the imposed clawback regarding Greek pharmaceutical expenditure for 2017 vs 2016 and another 30% for 2018 vs 2017 is welcome, as is the inclusion of this provision in Greece’s draft national budget for 2017.

It is paramount that the Commission closely monitor that the stated 30% reduction in the clawback will be achieved by means of structural and permanent measures that will help Greece’s pharmaceutical industry recover and invest according to its true potential. Securing the sustainability of Greece’s second most dynamic export market is crucial for affordable access to medicines and the promotion of innovation.

1. Will the Commission continue monitoring the implementation of agreed structural reforms for reducing the clawback, such as the therapeutic protocols, the legal framework of the Negotiation Committee for innovative medicines and the creation of the health technology assessment (HTA) organisation?

2. Will it accept an artificial 30% reduction, for example by transferring the clawback reduction to increased rebates?